EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Durable Complete Response to Pembrolizumab for Postoperative Nodal Recurrence of Lynch Syndrome–Associated Upper Tract Urothelial Carcinoma: A Case Report

Kaya Atagi, Shinkuro Yamamoto iD, Nobutaka Shimizu iD, Mitsuko Iguchi, Ryu Shigehisa iD, Tomoya Nao iD, Tsutomu Shimamoto iD, Hideo Fukuhara iD, Satoshi Fukata iD, Keiji Inoue

IJU Case Reports · 2026-11 · 9 (6)

DOI: 10.1002/iju5.70293 ↗

Kurz gefasst

Fallbericht in der Zeitschrift IJU Case Reports, online erschienen am 02.11.2026. Verfasst von Kaya Atagi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kochi Medical School Kochi University Nankoku Japan. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kochi University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Germline mutations in mismatch repair genes cause Lynch syndrome and are associated with upper tract urothelial carcinoma (UTUC). Tumors with deficient mismatch repair (dMMR) or microsatellite instability–high (MSI‐H) may respond favorably to immune checkpoint inhibitors. Case Presentation A 54‐year‐old woman with Lynch syndrome and a germline MSH2 mutation developed right renal pelvic carcinoma. The tumor was diagnosed as a pT3 high‐grade urothelial carcinoma, and the patient underwent laparoscopic nephroureterectomy. She was subsequently administered adjuvant gemcitabine and carboplatin due to a contraindication for cisplatin. Due to nodal recurrence, pembrolizumab was initiated at 200 mg every 3 weeks, achieving a complete radiological and metabolic response after five cycles. The course was complicated by immune‐related adrenal insufficiency, which was managed with corticosteroid replacement therapy.

Conclusion

Pembrolizumab may achieve a durable complete response in Lynch syndrome–associated UTUC. MSI screening should be considered in UTUC to guide decision‐making.

Schlagwörter

Stichwörter der Autor:innen

Lynch syndromecomplete responsemicrosatellite instabilitypembrolizumabupper tract urothelial carcinoma

Autor:innen und Institutionen

  • Department of Urology, Kochi Medical School Kochi University Nankoku Japan.
  • Pelvic Floor Center, Kochi Medical School Kochi University Nankoku Japan.
  • Department of Diagnostic Pathology, Kochi Medical School Kochi University Nankoku Japan.

ORCID-Profile: Shinkuro Yamamoto, Nobutaka Shimizu, Ryu Shigehisa, Tomoya Nao, Tsutomu Shimamoto, Hideo Fukuhara, Satoshi Fukata

Förderung

  • Kochi University

Zitieren

APA

Atagi, K., Yamamoto, S., Shimizu, N., Iguchi, M., Shigehisa, R., Nao, T., Shimamoto, T., Fukuhara, H., Fukata, S., & Inoue, K. (2026). Durable Complete Response to Pembrolizumab for Postoperative Nodal Recurrence of Lynch Syndrome–Associated Upper Tract Urothelial Carcinoma: A Case Report. IJU Case Reports, 9(6). https://doi.org/10.1002/iju5.70293

Vancouver

Atagi K, Yamamoto S, Shimizu N, Iguchi M, Shigehisa R, Nao T, et al. Durable Complete Response to Pembrolizumab for Postoperative Nodal Recurrence of Lynch Syndrome–Associated Upper Tract Urothelial Carcinoma: A Case Report. IJU Case Reports. 2026;9(6). doi:10.1002/iju5.70293

BibTeX
@article{Atagi2026,
  author = {Atagi, Kaya and Yamamoto, Shinkuro and Shimizu, Nobutaka and Iguchi, Mitsuko and Shigehisa, Ryu and Nao, Tomoya and Shimamoto, Tsutomu and Fukuhara, Hideo and Fukata, Satoshi and Inoue, Keiji},
  title = {Durable Complete Response to Pembrolizumab for Postoperative Nodal Recurrence of Lynch Syndrome–Associated Upper Tract Urothelial Carcinoma: A Case Report},
  journal = {IJU Case Reports},
  year = {2026},
  volume = {9},
  number = {6},
  doi = {10.1002/iju5.70293}
}
Kostenlos starten →